National Hepatitis C estimates : Incidence, prevalence, undiagnosed proportion and treatment, Canada, 2019
Background: Estimates of the number of hepatitis C virus (HCV) infections are important for monitoring efforts aimed at preventing disease transmission, especially following the introduction of a highly effective treatment. This report provides updated estimates of HCV incidence, prevalence, undiagnosed proportion and treatment in Canada.
Methods: A combination of back calculation modelling and a modified version of the workbook method were used to estimate the incidence and prevalence of anti-HCV positive persons, the prevalence of chronic HCV infection and the undiagnosed proportion. The number of people treated for chronic HCV was estimated using administrative pharmaceutical data.
Results: An estimated 9,470 new infections occurred in 2019, corresponding to an incidence rate of 25 per 100,000 population, a 7.7% decrease since 2015. The estimated prevalence of anti-HCV antibodies in the Canadian population was 1.03% (plausible range: 0.83%-1.38%), and the estimated prevalence of chronic HCV was 0.54% (plausible range: 0.40%-0.79%). The overall proportion of anti-HCV positive persons who were undiagnosed was estimated at 24% of all infections, with individuals born between 1945 and 1975 being the priority population the most likely to be undiagnosed. An estimated 74,500 people with chronic HCV have been treated since the introduction of direct-acting antivirals in 2014.
Conclusion: Estimates of HCV incidence and prevalence are key metrics to guide interventions and resource allocation. While our estimates show that HCV incidence has decreased in Canada in recent years and treatment of chronic HCV has continued to increase, ongoing efforts are required to reduce the burden of HCV in Canada.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:48 |
|---|---|
| Enthalten in: |
Canada communicable disease report = Releve des maladies transmissibles au Canada - 48(2022), 11-12 vom: 03. Nov., Seite 540-549 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Popovic, Nashira [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Canada |
|---|
| Anmerkungen: |
Date Revised 16.01.2024 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.14745/ccdr.v48i1112a07 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367133806 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367133806 | ||
| 003 | DE-627 | ||
| 005 | 20240116232057.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240115s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.14745/ccdr.v48i1112a07 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1261.xml |
| 035 | |a (DE-627)NLM367133806 | ||
| 035 | |a (NLM)38222827 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Popovic, Nashira |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a National Hepatitis C estimates |b Incidence, prevalence, undiagnosed proportion and treatment, Canada, 2019 |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 16.01.2024 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Background: Estimates of the number of hepatitis C virus (HCV) infections are important for monitoring efforts aimed at preventing disease transmission, especially following the introduction of a highly effective treatment. This report provides updated estimates of HCV incidence, prevalence, undiagnosed proportion and treatment in Canada | ||
| 520 | |a Methods: A combination of back calculation modelling and a modified version of the workbook method were used to estimate the incidence and prevalence of anti-HCV positive persons, the prevalence of chronic HCV infection and the undiagnosed proportion. The number of people treated for chronic HCV was estimated using administrative pharmaceutical data | ||
| 520 | |a Results: An estimated 9,470 new infections occurred in 2019, corresponding to an incidence rate of 25 per 100,000 population, a 7.7% decrease since 2015. The estimated prevalence of anti-HCV antibodies in the Canadian population was 1.03% (plausible range: 0.83%-1.38%), and the estimated prevalence of chronic HCV was 0.54% (plausible range: 0.40%-0.79%). The overall proportion of anti-HCV positive persons who were undiagnosed was estimated at 24% of all infections, with individuals born between 1945 and 1975 being the priority population the most likely to be undiagnosed. An estimated 74,500 people with chronic HCV have been treated since the introduction of direct-acting antivirals in 2014 | ||
| 520 | |a Conclusion: Estimates of HCV incidence and prevalence are key metrics to guide interventions and resource allocation. While our estimates show that HCV incidence has decreased in Canada in recent years and treatment of chronic HCV has continued to increase, ongoing efforts are required to reduce the burden of HCV in Canada | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Canada | |
| 650 | 4 | |a Hepatitis C | |
| 650 | 4 | |a epidemiology | |
| 650 | 4 | |a incidence | |
| 650 | 4 | |a prevalence | |
| 700 | 1 | |a Williams, Anson |e verfasserin |4 aut | |
| 700 | 1 | |a Périnet, Simone |e verfasserin |4 aut | |
| 700 | 1 | |a Campeau, Laurence |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Qiuying |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Fan |e verfasserin |4 aut | |
| 700 | 1 | |a Yan, Ping |e verfasserin |4 aut | |
| 700 | 1 | |a Feld, Jordan |e verfasserin |4 aut | |
| 700 | 1 | |a Janjua, Naveed |e verfasserin |4 aut | |
| 700 | 1 | |a Klein, Marina |e verfasserin |4 aut | |
| 700 | 1 | |a Krajden, Mel |e verfasserin |4 aut | |
| 700 | 1 | |a Wong, William |e verfasserin |4 aut | |
| 700 | 1 | |a Cox, Joseph |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Canada communicable disease report = Releve des maladies transmissibles au Canada |d 1994 |g 48(2022), 11-12 vom: 03. Nov., Seite 540-549 |w (DE-627)NLM012649449 |x 1188-4169 |7 nnns |
| 773 | 1 | 8 | |g volume:48 |g year:2022 |g number:11-12 |g day:03 |g month:11 |g pages:540-549 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.14745/ccdr.v48i1112a07 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 48 |j 2022 |e 11-12 |b 03 |c 11 |h 540-549 | ||